Stocklytics Platform
Asset logo for symbol EDIT
Editas Medicine
EDIT73
$1.38arrow_drop_down2.48%-$0.03
Penny Stock
Asset logo for symbol EDIT
EDIT73

$1.38

arrow_drop_down2.48%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Editas Medicine (EDIT) Stocklytics Forecast

Editas Medicine Inc (EDIT) is a leading genome editing company that is focused on developing transformative gene editing therapies. The company has made significant progress in the field of CRISPR technology and has a strong pipeline of potential treatments for a variety of diseases. As a result, there is a lot of interest in Editas Medicine and its stock price forecast.
There are several factors that could affect the future stock price of Editas Medicine. Firstly, the successful development and commercialization of their gene editing therapies could have a significant impact on the company's valuation. If Editas Medicine is able to bring its innovative treatments to market, it could experience substantial revenue growth, which could drive its stock price higher.
add Editas Medicine  to watchlist

Keep an eye on Editas Medicine

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Editas Medicine (EDIT) stock?

Analysts have set a target price of $12.79 for Editas Medicine (EDIT), based on forecasts from 29 analysts. The predicted price range extends from a high of $22 to a low of $6. This represents a potential increase of up to 1.49K% and a decrease of 334.78% from the current price of $1.38. These forecasts are as of 2023 Jan 10.
help

What are the analyst ratings for Editas Medicine (EDIT) stock?

The analyst ratings for Editas Medicine (EDIT) are distributed as follows: 4 analysts recommend buying, 12 have a neutral stance, and 2 suggest selling. The prevailing sentiment among the total of 18 analysts leans towards a neutral rating. These ratings indicate the general sentiment among the analysts covering Editas Medicine .
help

What is the AI price prediction for Editas Medicine (EDIT) stock?

At present, there is no AI or machine-learning-based price prediction available for Editas Medicine (EDIT) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level